| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Vincristine sulfate (also known as Leurocristine; NSC67574; NSC-67574; Vincasar PFS, Oncovin, VCR), the sulfate salt of Vincristine which is a naturally occurring alkaloid isolated from the plant Vinca rosea Linn and an approved anticancer drug, is a potent inhibitor of microtubule polymerization by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine is extracted from leaves of the periwinkle plant Catharanthus roseus (L.) G. Don of the family Apocynaceae. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism.
| ln Vitro |
Vincristine, with a Ki of 85 nM, inhibits the net addition of tubulin dimers at the assembly ends of steady-state microtubules[1]. At low doses, vincristine inhibits mitosis and causes metaphase arrest by stabilizing the spindle apparatus, which prevents the chromosomes from segregating. Vincristine has the potential to cause complete depolymerization of microtubules when used at higher concentrations [2]. With an IC50 of 0.1 μM, vincristine suppresses the proliferation of SH-SY5Y cells and causes apoptosis in tumor cells. Vincristine decreases the expression of cyclin D while inducing mitotic arrest and promoting the production of caspase-3, -9, and cyclin B[3]. Vincristine-induced neurotoxicity is brought on by disruption of microtubule activity, which obstructs axonal transport and ultimately causes axonal degeneration[4].
|
||
|---|---|---|---|
| ln Vivo |
Vincristine (3 mg/kg, i.p.) given to mice receiving bilateral subcutaneous xenografts of Rh12 or Rh18, respectively, causes a mean growth delay of more than 120 and more than 52 days and repopulates fractions of 0.06% and 5%[5].
|
||
| Animal Protocol |
|
||
| References |
[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.
[2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108 |
| Molecular Formula |
C46H58N4O14S
|
|---|---|
| Molecular Weight |
923.04
|
| CAS # |
2068-78-2
|
| Related CAS # |
Vincristine-d3-ester sulfate;1217854-24-4;Vincristine-d3 sulfate;1246817-10-6;Vincristine-d6 sulfate
|
| SMILES |
O=C([C@]1(O)[C@]2([H])N(C=O)C3=C(C=C([C@@]4(C(OC)=O)C[C@@]5([H])C[C@@](O)(CC)C[N@](C5)CCC6=C4NC7=C6C=CC=C7)C(OC)=C3)[C@]2(CCN8CC=C9)[C@]8([H])[C@]9(CC)[C@H]1OC(C)=O)OC.O=S(O)(O)=O
|
| Chemical Name |
(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-ethyl-9-((3S,5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-2,4,5,6,7,8,9,10-octahydro-1H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate.
|
| Synonyms |
Leurocristine; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate; leurocristine sulfate; NSC67574; NSC 67574; Vincasar PFS, Oncovin, VCR
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0834 mL | 5.4169 mL | 10.8338 mL | |
| 5 mM | 0.2167 mL | 1.0834 mL | 2.1668 mL | |
| 10 mM | 0.1083 mL | 0.5417 mL | 1.0834 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA